DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin degludec

First Posted Date: 2023-12-01

Last Posted Date: 2024-07-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 175

Registration Number: NCT06153537

Locations: 🇸🇦
My clinic, Jeddah, Saudi Arabia
🇸🇦
Al Hammadi, Riyadh, Saudi Arabia
🇸🇦
Almoosa Specialist Hospital, Ihsaa, Saudi Arabia

and more 8 locations

A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults.

Phase 1

Completed

Conditions: Healthy Volunteers - Liver Diseases

Interventions: Drug: Placebo (NNC0560-0004)
Drug: NNC0560-0004

First Posted Date: 2023-11-15

Last Posted Date: 2024-08-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 51

Registration Number: NCT06133270

Locations: 🇬🇧
Northwick Park Hosptial, Watford, Middlesex, United Kingdom

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

Phase 3

Active, not recruiting

Conditions: Obesity

Interventions: Drug: Cagrilintide
Drug: Tirzepatide
Drug: Semaglutide

First Posted Date: 2023-11-14

Last Posted Date: 2025-05-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 809

Registration Number: NCT06131437

Locations: 🇺🇸
Great Lakes Clinical Trials, Chicago, Illinois, United States
🇺🇸
Univ of Colorado at Denver, Aurora, Colorado, United States
🇺🇸
Northeast Research Institute, Fleming Island, Florida, United States

and more 42 locations

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

Phase 2

Active, not recruiting

Conditions: Chronic Kidney Disease
Type 2 Diabetes
Obesity

Interventions: Drug: Cagrilintide
Drug: Semaglutide
Drug: Placebo

First Posted Date: 2023-11-14

Last Posted Date: 2025-05-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 618

Registration Number: NCT06131372

Locations: 🇸🇰
Univerzitna nemocnica L. Pasteura Kosice, Kosice, Slovakia
🇭🇺
Szent Margit Rendelőintézet Nonprofit Kft., Budapest, Hungary
🇭🇺
Békés Megyei Központi Kórház, Gyula, Hungary

and more 106 locations

Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

Completed

Conditions: Chronic Kidney Disease
Heart Failure
Cardiovascular Risk

Interventions: Other: No treatment given

First Posted Date: 2023-11-08

Last Posted Date: 2025-05-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 18198

Registration Number: NCT06122961

Locations: 🇧🇷
Hospital do Coração do Brasil, Brasília, Brazil
🇧🇷
IPECC - Instituto de Pesquisa Clínica de Campinas, Campinas, Brazil
🇧🇷
HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás, Goiânia, Brazil

and more 191 locations

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

Phase 3

Recruiting

Conditions: Cardiovascular Risk
Acute Myocardial Infarction (AMI)

Interventions: Drug: Placebo
Drug: Ziltivekimab

First Posted Date: 2023-11-07

Last Posted Date: 2025-04-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 10000

Registration Number: NCT06118281

Locations: 🇧🇬
MHAT MC-Sv Ivan Rilski EOOD, Plovdiv, Bulgaria
🇧🇬
'MHAT Sveta Karidad' EAD, Plovdiv, Bulgaria
🇧🇬
Specialized Hospital For Active Cardiology Treatment Medica Kor EAD, Ruse, Bulgaria

and more 753 locations

A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes

Withdrawn

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: IDegLira

First Posted Date: 2023-11-02

Last Posted Date: 2024-09-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 266

Registration Number: NCT06113341

Locations: 🇮🇹
Azienda Ospedaliero-Universitaria Renato Dulbecco, Catanzaro, Italy
🇮🇹
Ospedale San Francesco d'Assisi, Oliveto Citra, Italy
🇮🇹
Presidio Ospedaliero Santa Barbara, Iglesias, Italy

and more 15 locations

Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed

Conditions: Growth Hormone Deficiency in Children

Interventions: Drug: Somapacitan

First Posted Date: 2023-10-31

Last Posted Date: 2024-08-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 200

Registration Number: NCT06109935

Locations: 🇯🇵
Asahikawa Medical Univ. Hospital, Pediatrics, Asahikawa, Hokkaido, Japan
🇯🇵
Beppu Medical Center, Beppu-shi, Oita-ken, Japan
🇯🇵
Fukuoka University Hospital, Fukuoka-shi, Fukuoka-ken, Japan

and more 44 locations

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Semaglutide

First Posted Date: 2023-10-24

Last Posted Date: 2024-07-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 121

Registration Number: NCT06097390

Locations: 🇨🇦
Altasciences Clinical Company, Inc, Montreal, Quebec, Canada

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

Phase 3

Withdrawn

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide
Drug: Metformin
Drug: Empagliflozin

First Posted Date: 2023-10-16

Last Posted Date: 2024-02-26

Lead Sponsor: Novo Nordisk A/S

Registration Number: NCT06083675

Locations: 🇹🇭
Songklanagarind Hospital, Songkla, Thailand
🇬🇷
General Hospital of Thessaloniki "G.Papanikolaou", Thessaloniki, Greece
🇵🇱
ETG Siedlce, Siedlce, Masovian, Poland

and more 97 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy